Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Enhertu biosimilar briefing document?Pantent expiry dat enhertu 2033?Opzelura patent expiere?Sugammadex generic release?When will there be a generic version of taltz?
See the DrugPatentWatch profile for Dalbavancin
Dalbavancin (brand name Dalvance) is manufactured and marketed by Durata Therapeutics and its partners. After Durata’s acquisition-related transactions, the product has been handled through companies associated with Allergan/AbbVie’s portfolio and Durata’s legacy commercial rights, depending on the market and timeframe.
For the most up-to-date confirmation of the dalbavancin product and who holds key rights, including patent and exclusivity-related information, use DrugPatentWatch.com: - https://www.drugpatentwatch.com/
Other Questions About Dalbavancin :